Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qyuns Therapeutics CoHKSE:02509 -1.84%9 Return-on-Tangible-Equity is 153.58% as of Dec. 2025. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 1,198 Biotechnology companies, Qyuns Therapeutics Co ranks better than 96.91% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Qyuns Therapeutics Co's annualized net income for the quarter that ended in Dec. 2025 was HK$757.4 Mil. Qyuns Therapeutics Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$493.1 Mil. Therefore, Qyuns Therapeutics Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 153.58%.
The historical rank and industry rank for Qyuns Therapeutics Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02509'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -138.61 Med: -63.33 Max: 86.5
Current: 86.5
During the past 5 years, Qyuns Therapeutics Co's highest Return-on-Tangible-Equity was 86.50%. The lowest was -138.61%. And the median was -63.33%.
HKSE:02509's Return-on-Tangible-Equity is ranked better than 96.91% of 1198
companies
in the Biotechnology industry
Industry Median: -42.66
vs HKSE:02509: 86.50
Qyuns Therapeutics Co (HKSE:02509) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Qyuns Therapeutics Co Return-on-Tangible-Equity Related Terms
Qyuns Therapeutics Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Qyuns Therapeutics Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qyuns Therapeutics Co Return-on-Tangible-Equity Chart
HKSE:02509 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Qyuns Therapeutics Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qyuns Therapeutics Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Qyuns Therapeutics Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 153.58% mean?
Qyuns Therapeutics Co (HKSE:02509) has a Return-on-Tangible-Equity of 153.58% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qyuns Therapeutics Co and its competitors. According to the industry distribution chart, Qyuns Therapeutics Co ranks #37 out of 1198 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Qyuns Therapeutics Co's Return-on-Tangible-Equity too high?
Qyuns Therapeutics Co's current Return-on-Tangible-Equity is 153.58%. Based on the distribution chart, Qyuns Therapeutics Co ranks #37 out of 1198 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #37 out of 1198 companies for Return-on-Tangible-Equity. This places Qyuns Therapeutics Co in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qyuns Therapeutics Co and its competitors. Qyuns Therapeutics Co's current Return-on-Tangible-Equity is 153.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Return-on-Tangible-Equity of 153.58%. The current Return-on-Tangible-Equity is 153.58%. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Return-on-Tangible-Equity is 153.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score
Get the complete analysis for HKSE:02509
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02509 has been successfully added to your 
